Skip to main content
Equibles
BZYR logo

BZYR · Burzynski Research Institute Inc

Track BZYR — free

Use BZYR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BZYR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Oct 12
Rebalance outlook locked
Going-concern doubt — flagged Jan 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has not generated significant revenue since its inception, has incurred recurring operating losses, has a working capital deficit and an accumulated deficit, and has experienced negative operating cash flows. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”
View the 10-Q filed Jan 13, 2026
Market Cap
$26,289
Shares
131.45M
Volume · Oct 12 10K Avg daily vol (15 sessions) 54.73K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.05 Avg vol 30d36K Short int285 · 0.0% of shares · 1.0d Short vol100% DataJan 2020–Oct 2026 Filing10-Q · Jan 13

Latest documents

2026
May 12
Current report 8-K Events of May 7
Other events AI summary on its way
2025
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$1.29M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2,165
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-99.5%
Trailing year
Short interest
—
Latest settlement
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −99%
below
Price vs 50-day avg −98%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −97%
trailing
6-month return −99%
trailing
YTD return −99%
this year
Relative strength −110%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Strong
EPS growth 0%
Y/Y
Balance sheet $847
net cash
Quant / Vol
risk profile
Very High
Volatility 464%
annualized · 1-yr
Max drawdown −100%
past year
ATR 1000.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−99% Bearish
Price vs 50-day avg
−98% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $0
vs 200-day avg -99% vs 50-day avg -98%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BZYR
Burzynski Research Institute Inc
this stock
$26,289 -98.9% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc
 $137.57B +19.7% +46.2% 34.9 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.40B +23.2% +20.8% 21.0 2.1%
MRNA
Moderna, Inc.
 $93.61B +684.5% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
285
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Sep 3, 2026
Short Total
View
Fails to Deliver
FTD shares
5.6K
Value
$223
As of
Apr 25, 2025
View
Off-Exchange
Off-exchange %
1.4%
Week of
Sep 28, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-1.4M
EPS diluted
$-0.01
View
Filings
SEC Filings
Latest
8-K
Filed
May 12, 2026
This year
3
View

Performance

5D 20D 120D MTD YTD
BZYR -90.0% -96.7% -99.4% -90.0% -99.0%
SPY +0.4% +2.3% +10.5% +2.0% +14.1%
vs SPY -90.4% -98.9% -109.9% -92.0% -113.1%
Key facts CIK 724445